NIKKEI 225
38,920.26 +534.53 (+1.39%) HANG SENG
19,376.53 +302.82 (+1.59%) CRUDE OIL
79.28 +0.65 (+0.83%) GOLD FUTURES
2,383.60 -11.30 (-0.47%) DOW
39,905.23 -2.77 (-0.01%) Bitcoin GBP
51,484.57 -810.42 (-1.55%)
BioPorto A/S (0JJM.L)
| Previous close | 2.2050 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 7,644 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2140 |
| Earnings date | 15 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireFirst Quarter 2024: Strong growth in US sales of The NGAL Test
May 8, 2024 Announcement no. 11 First Quarter 2024: Strong growth in US sales of The NGAL Test COPENHAGEN, Denmark and BOSTON, MA, USA, May 8, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announced interim financial results for the first three months of 2024 and business progress for the first quarter of 2024. Financial Highlights For the th
Globe NewswireBioPorto A/S Appoints President and CEO of BioPorto Inc.
May 7, 2024News release BioPorto A/S Appoints President and CEO of BioPorto Inc. COPENHAGEN, DENMARK and BOSTON, MA, USA, May 7, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today the appointment of Jeffrey N. Haas as new President and Chief Executive Officer of BioPorto Inc. (US), the fully owned subsidiary of BioPorto, and member of the Group’s Executi
- Globe Newswire
BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting
May 2, 2024News release BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, May 2, 2024 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, in connection with the release of its Interim Report for the first quarter ending March 31, 2024, the Company’s management team will host an online
